与皮下注射替诺福韦相比，口服替诺福韦富马酸酯在感染猴免疫缺陷病毒的猕猴体内将药物优先集中到肠道相关淋巴样细胞中。
Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.
机构信息
California National Primate Research Center, University of California, Davis, California, USA.
出版信息
Antimicrob Agents Chemother. 2012 Sep;56(9):4980-4. doi: 10.1128/AAC.01095-12. Epub 2012 Jul 9.
Abstract
To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate (TDF) versus subcutaneous tenofovir (TFV), macaques were treated for 2 weeks starting 1 week after simian immunodeficiency virus inoculation. Despite lower plasma TFV levels in the oral TDF arm, similar TFV diphosphate levels and antiviral activities were measured in lymphoid cells of most tissues. In intestinal tissues, however, oral TDF resulted in higher active drug levels, associated with lower virus levels and better immune preservation.
摘要
为了比较口服替诺福韦二吡呋酯（TDF）与替诺福韦（TFV）的组织药代动力学和疗效，猕猴在感染猴免疫缺陷病毒 1 周后开始接受为期 2 周的治疗。尽管口服 TDF 组的血浆 TFV 水平较低，但在大多数组织的淋巴细胞中测量到相似的 TFV 二磷酸酯水平和抗病毒活性。然而，在肠道组织中，口服 TDF 导致更高的活性药物水平，与更低的病毒水平和更好的免疫保护相关。
相似文献
1
Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.
Antimicrob Agents Chemother. 2012 Sep;56(9):4980-4. doi: 10.1128/AAC.01095-12. Epub 2012 Jul 9.
2
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Antimicrob Agents Chemother. 2008 Sep;52(9):3144-60. doi: 10.1128/AAC.00350-08. Epub 2008 Jun 23.
3
Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.
J Virol. 2011 Jul;85(13):6610-7. doi: 10.1128/JVI.00311-11. Epub 2011 Apr 27.
4
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
J Virol. 2012 Jan;86(2):718-25. doi: 10.1128/JVI.05842-11. Epub 2011 Nov 9.
5
Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.
Mol Pharm. 2009 Jul-Aug;6(4):1145-51. doi: 10.1021/mp900036s.
6
Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
J Infect Dis. 2013 Aug 1;208(3):463-7. doi: 10.1093/infdis/jit189. Epub 2013 Apr 30.
7
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus.
J Acquir Immune Defic Syndr. 2006 Sep;43(1):6-14. doi: 10.1097/01.qai.0000224972.60339.7c.
8
Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
J Med Primatol. 2003 Aug;32(4-5):201-10. doi: 10.1034/j.1600-0684.2003.00026.x.
9
Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
Antimicrob Agents Chemother. 2012 Jan;56(1):103-9. doi: 10.1128/AAC.00597-11. Epub 2011 Oct 10.
10
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
J Virol. 2000 Feb;74(4):1767-74. doi: 10.1128/jvi.74.4.1767-1774.2000.
引用本文的文献
1
SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity.
Nat Commun. 2024 Dec 4;15(1):10550. doi: 10.1038/s41467-024-54783-0.
2
Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques.
Front Immunol. 2023 Sep 18;14:1213455. doi: 10.3389/fimmu.2023.1213455. eCollection 2023.
3
Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture.
J Pharm Sci. 2022 Feb;111(2):529-541. doi: 10.1016/j.xphs.2021.10.007. Epub 2021 Oct 19.
4
A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02320-20.
5
The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
Clin Pharmacol Ther. 2020 Nov;108(5):971-975. doi: 10.1002/cpt.1883. Epub 2020 Jun 11.
6
Training rhesus macaques to take daily oral antiretroviral therapy for preclinical evaluation of HIV prevention and treatment strategies.
PLoS One. 2019 Nov 15;14(11):e0225146. doi: 10.1371/journal.pone.0225146. eCollection 2019.
7
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
J Control Release. 2018 Apr 10;275:229-241. doi: 10.1016/j.jconrel.2018.02.003. Epub 2018 Feb 10.
8
Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice.
Int J Toxicol. 2015 Jan-Feb;34(1):4-10. doi: 10.1177/1091581814565669. Epub 2015 Jan 7.
9
Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution.
PLoS One. 2014 Feb 5;9(2):e88258. doi: 10.1371/journal.pone.0088258. eCollection 2014.
本文引用的文献
1
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.
PLoS Pathog. 2012 Feb;8(2):e1002506. doi: 10.1371/journal.ppat.1002506. Epub 2012 Feb 2.
2
HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts.
Science. 2011 Dec 23;334(6063):1614. doi: 10.1126/science.334.6063.1614.
3
Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.
Antimicrob Agents Chemother. 2011 Nov;55(11):5294-9. doi: 10.1128/AAC.05317-11. Epub 2011 Sep 6.
4
The emerging race to cure HIV infections.
Science. 2011 May 13;332(6031):784-5, 787-9. doi: 10.1126/science.332.6031.784.
5
Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques.
Vaccine. 2011 Apr 12;29(17):3124-37. doi: 10.1016/j.vaccine.2011.02.051. Epub 2011 Mar 4.
6
Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Antimicrob Agents Chemother. 2011 Apr;55(4):1549-55. doi: 10.1128/AAC.00910-10. Epub 2011 Jan 31.
7
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
8
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.
Sci Transl Med. 2010 Jan 13;2(14):14ra4. doi: 10.1126/scitranslmed.3000391.
9
Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.
Mol Pharm. 2009 Jul-Aug;6(4):1145-51. doi: 10.1021/mp900036s.
10
HIV infection and the gastrointestinal immune system.
Mucosal Immunol. 2008 Jan;1(1):23-30. doi: 10.1038/mi.2007.1.
Zotero 插件